Matthew Herder and Srinivas Murthy

Matthew Herder and Srinivas Murthy

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

• The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of

Opinion | BY MATTHEW HERDER AND SRINIVAS MURTHY | April 19, 2021

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

Opinion | BY MATTHEW HERDER AND SRINIVAS MURTHY | April 19, 2021

• The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

Opinion | BY MATTHEW HERDER AND SRINIVAS MURTHY | April 19, 2021

• The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

• The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of

Opinion | BY MATTHEW HERDER AND SRINIVAS MURTHY | April 19, 2021

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

Opinion | BY MATTHEW HERDER AND SRINIVAS MURTHY | April 19, 2021

• The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of

A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada

Opinion | BY MATTHEW HERDER AND SRINIVAS MURTHY | April 19, 2021

• The $925-million public-private partnership to enhance the manufacturing capacity of Sanofi’s influenza vaccine facility in Toronto is only the latest in a string of

More Stories